Scholar Rock Holding Corp（SRRK）已重新向美国食品药品监督管理局（FDA）提交了其候选药物Apitegromab的生物制剂许可申请（BLA），该药物旨在用于治疗儿童及成人脊髓性肌萎缩症（SMA）患者。
此次重新提交标志着该公司在推进这一潜在疗法监管审批过程中的又一重要步骤。脊髓性肌萎缩症是一种严重的遗传性神经肌肉疾病，Apitegromab作为一种研究性疗法，旨在改善患者的肌肉功能和运动能力。
Scholar Rock Holding Corp（SRRK）已重新向美国食品药品监督管理局（FDA）提交了其候选药物Apitegromab的生物制剂许可申请（BLA），该药物旨在用于治疗儿童及成人脊髓性肌萎缩症（SMA）患者。
此次重新提交标志着该公司在推进这一潜在疗法监管审批过程中的又一重要步骤。脊髓性肌萎缩症是一种严重的遗传性神经肌肉疾病，Apitegromab作为一种研究性疗法，旨在改善患者的肌肉功能和运动能力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.